42
Participants
Start Date
March 20, 2003
Primary Completion Date
June 17, 2015
Study Completion Date
June 17, 2015
Mitoxantrone (Novantrone)
Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
Bortezomib (PS-341)
Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER